恒瑞医药启动“A+H”上市计划

Group 1 - The core point of the news is that Heng Rui Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international business development and drive innovation [1][5][6] - The company aims to use the funds raised from the H-share issuance for research and development, product commercialization, and operational activities, reflecting its commitment to the "innovation + internationalization" strategy [1][3] - Heng Rui Pharmaceutical reported a revenue of 20.189 billion yuan for the first three quarters, a year-on-year increase of 18.67%, and a net profit of 4.620 billion yuan, up 32.98% year-on-year, indicating stable growth [2][3] Group 2 - The company has invested over 40 billion yuan in research and development, with annual R&D expenditures exceeding 6 billion yuan from 2021 to 2023, and 4.549 billion yuan in the first three quarters of 2024, a 22% increase year-on-year [2][3] - Heng Rui's pipeline includes 17 innovative drugs approved in China, 4 Class 2 new drugs, and over 90 self-innovated products in clinical development, showcasing its strong R&D capabilities [2][4] - The company has entered over 40 countries with its high-end formulation products, including the FDA-approved paclitaxel albumin, and is actively pursuing international clinical trials and collaborations [4][5] Group 3 - The overseas listing is expected to accelerate Heng Rui's international expansion, providing access to a diverse range of international investors and enhancing its global brand image [5][6] - Recent policy support from the Hong Kong Securities and Futures Commission and the Stock Exchange aims to facilitate the listing process for A-share companies, creating a favorable environment for Heng Rui's dual listing strategy [5][6] - The company's focus on innovation and internationalization positions it to become a globally competitive multinational pharmaceutical group through the A+H dual listing model [6]